Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770978 · ClinicalTrials.gov registry record · Phase 1
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00770978 is a Phase 1 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 33 participants.
The verdict
NCT00770978, a Phase 1 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this research study is to measure the levels of ceftobiprole in the blood and urine during and after administration of four doses of ceftobiprole. Safety of the drug will also be evaluated.
Interventions
- DRUG ceftobiprole q12h
- DRUG ceftobiprole q8h
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770978
The ClinicalTrials.gov registry entry for NCT00770978 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ceftobiprole q12h is the first listed.
NCT00770978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770978 about?
NCT00770978 is a clinical study titled "Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU". The purpose of this research study is to measure the levels of ceftobiprole in the blood and urine during and after administration of four doses of ceftobiprole. Safety of the drug will also be evaluated.
What is the current status of trial NCT00770978?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-11. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00770978?
The interventions under investigation include: ceftobiprole q12h (DRUG), ceftobiprole q8h (DRUG).
Who is sponsoring clinical trial NCT00770978?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.